Effects of zaleplon or triazolam with or without ethanol on human performance - PubMed
Effects of zaleplon or triazolam with or without ethanol on human performance
T Roehrs et al. Sleep Med. 2001 Jul.
Abstract
Objectives and background: Given that non-selective gamma-aminobutyric acid (GABA) agonist hypnotics impair performance and potentiate the disruptive effects of ethanol, this study was done to determine the performance-impairing and ethanol-potentiating effects of zaleplon, a new selective GABA agonist hypnotic.Methods: Eighteen healthy men (12) and women (six), 31.5+/-5.6 years old, were studied. Each underwent six treatments of 2 days in duration, presented in a Latin square design with 2-12 recovery days between. The treatments were: placebo-placebo; placebo-ethanol; triazolam-placebo; triazolam-ethanol; zaleplon-placebo; and zaleplon-ethanol; with triazolam (0.25 mg) or placebo administered at 08:30 h, zaleplon (10 mg) or placebo at 09:00 h, and ethanol (0.75 g/kg) or placebo consumed from 09:30 h. Performance tests were completed each day at 10:30, 12:00 and 14:30 h.Results: Breath ethanol concentration (BrEC), tested 0.5, 2.0, 4.5 and 6 h post consumption, did not differ among treatments and peaked at 0.052%, declining to 0.037, 0.009 and 0.001%. Triazolam with and without ethanol impaired digit symbol substitution, symbol copying, simple and complex reaction times and divided attention performance relative to placebo-placebo treatment. It did so consistently at 10:30 and 12:00 h, and less consistently at 14:30 h. Zaleplon without ethanol impaired only digit symbol substitution and divided attention tracking, and only at 10:30 h. Zaleplon with ethanol impaired most measures at 10:30 and 12:00 h, but not at 14:30 h. Zaleplon without ethanol consistently differed from triazolam without ethanol in the extent of performance impairment. Zaleplon with ethanol began to differ from triazolam with ethanol in performance impairment on the 12:00 and 14:30 h test sessions. Ethanol itself impaired most measures at 10:30 h, fewer at 12:00 h and none at 14:30 h. All active drug treatments increased self-rated sleepiness compared with placebo-placebo. Triazolam without ethanol produced greater self-rated sleepiness than zaleplon without ethanol. The addition of ethanol to both drugs generally produced comparable levels of self-rated sleepiness.Conclusions: In an absolute sense, zaleplon produced less performance impairment and a shorter period of ethanol potentiation than triazolam.
Similar articles
-
Troy SM, Lucki I, Unruh MA, Cevallos WH, Leister CA, Martin PT, Furlan PM, Mangano R. Troy SM, et al. J Clin Psychopharmacol. 2000 Jun;20(3):328-37. doi: 10.1097/00004714-200006000-00007. J Clin Psychopharmacol. 2000. PMID: 10831020 Clinical Trial.
-
Zaleplon and triazolam in humans: acute behavioral effects and abuse potential.
Rush CR, Frey JM, Griffiths RR. Rush CR, et al. Psychopharmacology (Berl). 1999 Jul;145(1):39-51. doi: 10.1007/s002130051030. Psychopharmacology (Berl). 1999. PMID: 10445371 Clinical Trial.
-
Drake CL, Roehrs TA, Mangano RM, Roth T. Drake CL, et al. Hum Psychopharmacol. 2000 Dec;15(8):595-604. doi: 10.1002/hup.216. Hum Psychopharmacol. 2000. PMID: 12404612
-
Zaleplon: a review of its use in the treatment of insomnia.
Dooley M, Plosker GL. Dooley M, et al. Drugs. 2000 Aug;60(2):413-45. doi: 10.2165/00003495-200060020-00014. Drugs. 2000. PMID: 10983740 Review.
-
Zaleplon - a review of a novel sedative hypnotic used in the treatment of insomnia.
Heydorn WE. Heydorn WE. Expert Opin Investig Drugs. 2000 Apr;9(4):841-58. doi: 10.1517/13543784.9.4.841. Expert Opin Investig Drugs. 2000. PMID: 11060714 Review.
Cited by
-
Comparative tolerability of newer agents for insomnia.
Zammit G. Zammit G. Drug Saf. 2009;32(9):735-48. doi: 10.2165/11312920-000000000-00000. Drug Saf. 2009. PMID: 19670914 Review.
-
Clinically important drug interactions with zopiclone, zolpidem and zaleplon.
Hesse LM, von Moltke LL, Greenblatt DJ. Hesse LM, et al. CNS Drugs. 2003;17(7):513-32. doi: 10.2165/00023210-200317070-00004. CNS Drugs. 2003. PMID: 12751920 Review.
-
Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).
Chan LN, Anderson GD. Chan LN, et al. Clin Pharmacokinet. 2014 Dec;53(12):1115-36. doi: 10.1007/s40262-014-0190-x. Clin Pharmacokinet. 2014. PMID: 25267448 Review.
-
Miyata A, Iwamoto K, Kawano N, Kohmura K, Yamamoto M, Aleksic B, Ebe K, Noda A, Noda Y, Iritani S, Ozaki N. Miyata A, et al. Psychopharmacology (Berl). 2015 Jun;232(12):2127-37. doi: 10.1007/s00213-014-3843-4. Epub 2014 Dec 24. Psychopharmacology (Berl). 2015. PMID: 25533998 Clinical Trial.
-
Benefit-risk assessment of zaleplon in the treatment of insomnia.
Barbera J, Shapiro C. Barbera J, et al. Drug Saf. 2005;28(4):301-18. doi: 10.2165/00002018-200528040-00003. Drug Saf. 2005. PMID: 15783240 Review.